Effectiveness Transfer Energy Capacitive and Resistive Therapy in Patients With Carpal Tunnel Syndrome

Carpal Tunnel Syndrome Clinical Trial

Official title:

Comparison of the Effectiveness of Ultrasound and Transfer Energy Capacitive and Resistive (TECAR) Therapy in Patients With Carpal Tunnel Syndrome

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT06451094
• Other study ID #: E2-23-3833
• Status: Completed
• Phase: N/A
• Start date: May 15, 2023
• Est. completion date: February 15, 2024

Study information

• Verified date: June 2024
• Source: Ankara City Hospital Bilkent
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Objective: The aim of this study was to evaluate the effect of Transfer Energy Capacitive and Resistive (TECAR) therapy on pain, symptom severity and function in patients diagnosed with carpal tunnel syndrome (CTS) based on clinical and electromyography (EMG) findings and to compare it with ultrasound therapy (US).

Methods: A total of 42 patients aged between 18 and 65 years, were randomly divided into two groups; group 1, US therapy 5 minutes intermittently for 2 weeks, 5 times a week, for a total of 10 sessions, group 2 TECAR therapy 5 min capacitive (CAP) and 10 min resistive (RES), 3 days a week for 2 weeks, for a total of 6 sessions. Both groups received paraffin therapy and wrist orthosis. All Patients were evaluated using the Visual Analog Scale (VAS) for pain and paresthesia levels, the Boston Carpal Tunnel Questionnaire (BCTQ) for symptom severity and functional levels. Additionally, median nerve CSA was measured by ultrasound, at the baseline, post-treatment, first and third months.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 42
• Est. completion date: February 15, 2024
• Est. primary completion date: November 15, 2023
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• 18 years of age and over

• had pain and numbness in their hands for more than 3 months were evaluated

• Patients diagnosed with mild and moderate CTS by EMG

Exclusion Criteria:

• metabolic, rheumatic, or neurological diseases that could affect the median nerve cross-sectional area (CSA)

• patients who had previously undergone surgery on the wrist,

• oncology patients,

• pregnancy,

• pacemakers.

Related Conditions & MeSH terms

• Carpal Tunnel Syndrome
• Syndrome

Intervention

Device:
• US therapy
3 MHz probe with a BTL brand device at a dose of 1.5 watts/cm2 for 5 minutes intermittently for 2 weeks, 5 times a week, for a total of 10 sessions.
• TECAR
Transfer Energy Capacitative and Resistive Therapy

Locations

Country	Name	City	State
Turkey	Özge TEZEN	Ankara

Sponsors (1)

Lead Sponsor	Collaborator
Ankara City Hospital Bilkent

Country where clinical trial is conducted

Turkey, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Visual Analog Scale (VAS)	0 min , 10 is maximum pain score	baseline (0 th day), after-treatment (15 th day), 1th month, 3rd month
Primary	Boston Carpal Tunnel Questionnaire (BCTQ)	symptom severity on functional tasks (Symptom Severity Scale), involving 11 items, and the other one on function status properly (Functional Status Scale), involving 8 items. Both subscales of BCTQ are scored between 1 and 5, and higher scores illustrate a greater degree of disability.	baseline (0 th day), after-treatment (15 th day), 1th month, 3rd month
Secondary	Median nerve cross-sectional area (CSA) measurement	Median nerve CSA was measured by ultrasound on axial view at the scaphoid-pisiform level which is a reliable measurement for CTS. Three measurements were taken for analysis and the average value was recorded	baseline (0 th day), after-treatment (15 th day), 1th month, 3rd month